Cover -- Title -- Copyright -- Contents -- Preface -- Chapter 1: Gynecologic Oncology Referral Parameters -- I. Endometrial Cancer -- II. Pelvic Mass -- III. Cervical Cancer -- IV. Vaginal Cancer -- V. Vulvar Cancer -- VI. Gestational Trophoblastic Disease -- Chapter 2: Disease Sites -- A: Preinvasive Disease -- I. Cervical Intraepithelial Neoplasia (CIN) -- II. Vulvar Intraepithelial Neoplasia -- III. Vaginal Intraepithelial Neoplasia (VAIN) -- IV. Dysplasia and HIV -- References -- B: Cervical Cancer -- I. Characteristics -- II. Pretreatment Workup -- III. Histology -- IV. Staging -- V. Overall survival by stage -- VI. Treatment -- VII. Surgical Treatment -- VIII. Radiotherapy -- IX. Adjuvant Posthysterectomy Treatment -- X. Advanced Disease -- XI. Recurrent Disease -- XII. Survival -- XIII. Prognostic Factors for Survival -- XIV. Follow-Up -- XV. Notable Trials in Cervical Cancer -- References -- C: Ovarian Cancer -- I. General Characteristics -- II. General Workup -- III. General Treatment -- IV. Histology -- V. General Staging -- Epithelial Ovarian Cancer -- I. Characteristics -- II. Workup -- III. Histology -- IV. Staging -- V. Treatment -- VI. Chemotherapy for Epithelial Ovarian Cancer -- VII. Treatment by Stage -- VIII. Second-look laparotomy -- IX. Recurrence -- X. Secondary cytoreduction -- XI. Cerebellar degeneration -- XII. Survival -- XIII. Survival Care -- XIV. Epithelial Ovarian Cancer Trials -- Ovarian Tumors of Low Malignant Potential (LMP) -- I. Characteristics -- II. Histology -- III. Workup -- IV. Staging -- V. Treatment -- VI. Recurrence -- VII. Survival -- VIII. Survival Care -- Fallopian Tube Cancer -- I. Characteristics -- II. Workup -- III. Histology -- IV. Staging -- V. Treatment -- VI. Survival -- VII. Survival care -- Primary Peritoneal Cancer -- Germ Cell Tumors (GCT) -- I. Characteristics -- II. Workup.

III. Staging -- IV. Treatment -- V. Recurrence -- VI. Follow-Up -- VII. Histological Subtypes and Directed Therapies -- VIII. Germ Cell Tumor Trials -- IX. Chemotherapy Protocols for Ovarian GCT -- Sex Cord Stromal Tumors -- I. Characteristics -- II. Workup -- III. Staging -- IV. Treatment -- V. Histology -- VI. 5 Y Survival -- VII. Sex Cord Stromal Tumor Trials -- References -- D: Uterine Cancer -- I. Characteristics -- II. Prognostic factors -- III. Pretreatment Workup -- IV. Histology -- V. Staging -- VI. Grade is specified as a 3-tiered system -- VII. Treatment -- VIII. Recurrence -- IX. Postoperative hormonal replacement therapy -- X. Synchronous ovarian neoplasm -- XI. Survival -- XII. Follow-Up -- XIII. Tamoxifen -- Notable Studies in Uterine Cancer -- I. High-Risk Early-Stage Disease Adjuvant Therapy Studies -- Uterine Sarcomas -- I. Characteristics -- V. Prognostic factors -- VI. Follow-Up -- References -- E: Vulvar Cancer -- I. Characteristics -- II. Workup -- III. Histology -- IV. Staging -- V. Treatment -- VI. Recurrence -- VII. Survival -- VIII. Follow-up -- Notable Studies -- References -- F: Vaginal Cancer -- I. Characteristics -- II. Pretreatment Workup -- III. Histology -- IV. Staging -- V. Treatment -- VI. Recurrent Disease -- VII. Survival -- VIII. Follow-up -- G: Gestational Trophoblastic Disease -- I. Characteristics -- II. Histology -- III. Diagnosis -- IV . Workup -- V. Serum beta hCG -- VI. Staging -- VII. GTD Metastatic Sites -- VIII. Treatment -- IX. Management of Acute Disease-Induced Complications Can Be Lifesaving -- X. Chemotherapy Regimens -- XI. Resistant Disease -- XII. Recurrent Disease -- XIII. Follow-Up -- Important Gestational Trophoblastic Disease Trials -- References -- Chapter 3: Hereditary Cancer Syndromes -- I. Hereditary Breast and Ovarian Cancer (HBOC) -- II. Hereditary Nonpolyposis Colon Cancer (HNPCC).

References -- Chapter 4: Screening -- A: Ovarian Cancer Screening -- I. An ideal screening test -- II. HE4 -- III. CA-125 -- IV. Risk of Malignancy Index (ROMI) -- V. Roma (Risk of Ovarian Malignancy Algorithm) -- VI. The ROCA is the risk of ovarian cancer algorithm -- VII. The OVA-1 test utilizes 5 well-established biomarkers -- VIII. The ovarian cancer symptom index (SI) -- IX. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) -- X. The Prostate, Lung, Colon, and Ovarian Cancer Trial (PLCO) -- References -- B: Cervical Cancer Screening -- I. The HPV (human papilloma virus) -- II. Screening with Pap smears -- III. Pap smear reports -- IV. Cytologic guidelines -- References -- Chapter 5: Surgical Care -- A: Anatomy -- I. Layers of the abdomen -- II. Ligaments -- III. Vasculature -- IV. Nerves -- V. Vulvar and Groin Anatomy -- B: Surgical Devices -- I. Suture -- II. Drains -- III. Central Venous Catheters -- IV. Peritoneal Catheters -- V. Catheter Troubleshooting -- C: Surgical Procedures -- I. Laparotomy Incisions -- II. Incision Closure -- III. Lymph Node Dissection -- IV. Bowel Diversion -- V. Bowel Resection -- VI. Urinary Diversion: Stents, Conduits, and Bladder Reconstructions -- VII. Reconstructive surgery -- VIII. Splenectomy -- IX. Diaphragmatic stripping -- X. Minimally Invasive Surgery -- D: Intraoperative Complications -- I. Vascular Injury -- II. Nerve Injury -- III. Gastrointestinal Injury -- IV. Urinary Tract Injury -- V. Intraoperative Hemorrhage -- References -- E: Postoperative Care Protocols -- I. Radical Vulvar Surgery -- II. Radical Hysterectomy -- III. Urinary Conduits and Pelvic Exenteration -- IV. Bowel Resection -- V. Ovarian Cancer Debulking -- VI. Bowel Obstruction -- F: Postoperative Complications -- I. Gastrointestinal Complications -- II. Hemorrhage -- III. Postoperative Fever -- IV. Wound Infection.

V. Urinary Tract Injury -- VI. Lymphatic Complications -- VII. Nerve Injury -- Chapter 6: Medical Comorbidity Management -- A: Preoperative Risk Assessment -- I. Recommended laboratories -- II. ASA Score -- III. Cardiac Risk Score -- IV. Functional status -- V. Subacute Bacterial Endocarditis -- B: Perioperative Managementin Gynecologic Oncology -- I. Bowel Preparation -- II. Vascular Thromboembolism -- III. Nutrition -- IV. Endocrine Management -- V. Hepatic Disease -- VI. Neurologic Disease -- VII. Alcohol Withdrawal -- VIII. Blood Transfusion -- Reference -- C: Critical Care -- I. Pulmonary -- II. Cardiac -- III. Shock and Sepsis -- IV. Renal -- V. Acid-Base Disorders -- VI. Electrolyte Abnormalities -- VII. Fluids and Blood Products -- VIII. Neurologic -- IX. Abdominal compartment syndrome -- X. Risk stratification of morbidity and mortality -- Reference -- Chapter 7: Treatment Modalities -- A: Chemotherapy -- I. One Letter and Combination Chemotherapy Abbreviations -- II. Chemotherapy Definitions -- III. Delivery -- IV. Metabolism -- V. Principles of Chemotherapy Tumor Kill -- VI. Chemotherapy Regimens -- VII. Platinum Sensitivity/Resistance -- VIII. Toxicity -- IX. The Cell Cycle -- X. Growth Fraction -- XI. Cell Death -- XII. Log Kill -- XIII. Cell Cycle Nonspecific Chemotherapeutic Agents -- XIV. Cell Cycle Specific Agents -- XV. Cell Growth -- XVI. Mechanisms of Cytotoxicity -- XVII. Mechanisms of Resistance -- XVIII. Prior to Chemotherapy Administration -- Classes of Chemotherapy Agents And Independent Mechanisms of Action -- I. Alkylating Agents -- II. Antitumor Antibiotics -- III. Antimetabolites -- IV. Plant Alkaloids -- V. Hormonal Agents -- VI. Receptor and Signaling Targeted Therapies -- VII. Protective Agents -- VIII. Treatment of Extravasation Injury -- References -- B: Radiation Therapy -- I. Radiation Types -- II. Definitions.

III. Radiation Effects -- IV. Energy Equivalences -- V. Radiation Delivery -- VI. Tumoricidal Basics -- VII. The 4 R's of Radiation -- Disease Site Radiation Treatment -- I. Cervical Cancer -- II. Uterine Cancer -- III. Vulvar Cancer -- IV. Vaginal Cancer -- V. Ovarian Cancer -- Design of External Beam Radiation Fields -- I. Cervical Cancer -- II. Uterine Cancer -- III. Vulvar Cancer -- IV. Vaginal Cancer -- V. Ovarian Cancer -- VI. Whole Abdominal Radiotherapy (WAR) -- Radiation Effects -- I. The definition of an early complication is occurrence less than 3 months after completion of radiotherapy -- II. Skin toxicity -- III. Vaginal toxicity -- IV. Urinary tract toxicity -- V. Fistula formation -- VI. Bowel toxicity -- VII. Ovarian failure occurs -- VIII. Bone marrow toxicity -- IX. Liver toxicity can present as -- X. Renal toxicity -- XI. Fetal toxicity -- References -- Chapter 8: Reproductive Function and Cancer -- A: Sexual Function and Cancer -- References -- B: Fertility and Cancer Treatment -- I. Chemotherapeutic Drugs and Risk of infertility -- II. Radiation and Fertility -- C: Cancer in Pregnancy -- II. Radiation in Pregnancy -- III. Chemotherapy in Pregnancy -- IV. Cervical Cancer in Pregnancy -- V. Ovarian Neoplasms in Pregnancy -- VI. Other Gynecologic Cancers in Pregnancy -- References -- Chapter 9: Survival Care -- A: Surveillance Recommendations -- B: Surveillance Visit Checklist -- Checklist for Surveillance of Gynecologic Malignancies -- Reference -- Chapter 10: Palliative Care -- I. Palliative care -- II. Hospice -- IV. A multidisciplinary approach is important -- Active Dying (I.E., Transitioning) -- Ethical Issues -- Reference -- Chapter 11: Statistics -- I. Definitions -- III. The Receiver Operating Characteristic (ROC) -- IV. Endpoints of a study -- V. Phases of trials -- VI. Randomization Techniques -- VII. Eligibility criteria.

VIII. To avoid bias or confounding.